Koibuchi Harumi, Shibuya Yasuhiro, Kubo Nobuhiko, Kawano Mikihiko, Itoh Kouichi
Department of Clinical Laboratory Medicine, Jichi Medical School, Kawachi-gun, Tochigi 329-0498.
Rinsho Byori. 2002 Oct;50(10):992-9.
Clinical microbiology laboratories in Japan have not yet established standards for selecting the most appropriate antimicrobial agents for testing and reporting antimicrobial susceptibility that are comparable to the performance standards of the National Committee for Clinical Laboratory Standards(NCCLS) in the United States of America. Selection of the most appropriate antimicrobial agents for testing and reporting was discussed by a working group(WG) consisting of medical physicians, surgeons, pharmacists, medical technologists and medical microbiologists. The WG agreed on the following basic criteria for the selection of antimicrobial agents: 1) the agent should be useful when screening various resistant bacteria, 2) the agent should serve as a useful guide for physicians and residents when selecting antimicrobial agents, and 3) the agent should be useful for controlling nosocomial infections and resistant bacteria. Clinically isolated microorganisms were classified into 7 groups based on susceptibility to antimicrobial agents. These groups were Staphylococcus spp. or Enterococcus spp., Streptococcus spp. or Haemophilus spp., enterobacteriae, glucose non-fermenting gram positive rods(NFRs), anaerobic bacteria, fungi and mycobacterium. After considering clinical and bacteriological evidence, the WG decided on several antimicrobial agents for testing in clinical microbiology laboratories in Jichi Medical School Hospital. For the NFR group, these were Piperacillin(PIPC), ceftazidime(CAZ), cefepime, imipenem, amikacin and levofloxacin(LVFX). For the enterobacteriae group, these were Amplicillin(ABPC), PIPC, aztreonam, CAZ and LVFX. For the Staphylococcus spp. or Enterococcus spp. group, these were oxacillin, ABPC, vancomycin and gentamicin. We concluded that the most appropriate antimicrobial agent for testing and reporting must be economical and agreed upon at the hospital level, although the ultimate selection must be based on the available clinical and bacteriological evidence.
日本的临床微生物实验室尚未建立起与美国国家临床实验室标准委员会(NCCLS)性能标准相当的、用于选择最适宜抗菌药物进行检测及报告抗菌药物敏感性的标准。一个由内科医生、外科医生、药剂师、医学技术人员和医学微生物学家组成的工作组(WG)讨论了选择最适宜抗菌药物进行检测及报告的问题。该工作组就抗菌药物选择的以下基本标准达成了一致意见:1)该药物在筛查各种耐药菌时应有用;2)该药物在医生和住院医生选择抗菌药物时应能起到有用的指导作用;3)该药物在控制医院感染和耐药菌方面应有用。临床分离出的微生物根据对抗菌药物的敏感性被分为7组。这些组分别是葡萄球菌属或肠球菌属、链球菌属或嗜血杆菌属、肠杆菌科细菌、葡萄糖非发酵革兰氏阳性杆菌(NFRs)、厌氧菌、真菌和分枝杆菌。在考虑了临床和细菌学证据后,工作组确定了一些抗菌药物用于秩父医科大学医院临床微生物实验室的检测。对于NFR组,这些药物是哌拉西林(PIPC)、头孢他啶(CAZ)、头孢吡肟、亚胺培南、阿米卡星和左氧氟沙星(LVFX)。对于肠杆菌科细菌组,这些药物是氨苄西林(ABPC)、PIPC、氨曲南、CAZ和LVFX。对于葡萄球菌属或肠球菌属组,这些药物是苯唑西林、ABPC、万古霉素和庆大霉素。我们得出结论,用于检测及报告的最适宜抗菌药物必须经济实惠且在医院层面达成共识,尽管最终的选择必须基于现有的临床和细菌学证据。